Tests for a new drug, approved in Brazil, eliminate cancer in 100% of cases

Tests for a new drug, approved in Brazil, eliminate cancer in 100% of cases

The trial that confirmed the stunning findings got here from a small group of 12 sufferers with rectal cancer. In them, native researchers utilized a monoclonal antibody known as dostarlimab, which led to a favorable impact, and was supported for greater than a yr.

After therapy, magnetic resonance examination, endoscopic examination, digital rectal examination or biopsy discovered no proof of swelling.

As half of the examine, sufferers took the drug intravenously each three weeks for six months. “During the median follow-up interval of 12 months, no sufferers obtained chemotherapy and no sufferers underwent surgical resection.”

Luiz Diaz Jr., an oncologist, one of the authors of the work, in an interview with The New York Times, mentioned that analysis success charges in North America are uncommon, and that is in all probability the primary time such a factor has been recorded. throughout the nation.The historical past of cancer research.

The drug has the identify Jemperli – Photo: Disclosure/GSK

Dostarlimab is approved in Brazil for the therapy of endometrial cancer, and has by no means been examined for some other sort of tumor earlier than.

* With info from Exame Magazine

Follow Rnews on social media

Leave a Comment

Your email address will not be published.